	US 12,280,080 B2
	Antibacterial composition and uses thereof
Cindy Fevre, Paris (FR); Hélène Blois, Paris (FR); and Mathieu Medina, Saint Denis (FR)
Assigned to ERYTECH PHARMA, Lyons (FR)
Filed by ERYTECH PHARMA, Lyons (FR)
Filed on Jun. 30, 2023, as Appl. No. 18/344,924.
Application 18/344,924 is a continuation of application No. 16/491,176, granted, now 11,690,885, previously published as PCT/EP2018/055629, filed on Mar. 7, 2018.
Claims priority of application No. 17305245 (EP), filed on Mar. 8, 2017.
Prior Publication US 2024/0024391 A1, Jan. 25, 2024
Int. Cl. A61K 35/76 (2015.01); A01N 63/40 (2020.01); A61P 31/04 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12Q 1/18 (2006.01); A61K 38/00 (2006.01)

CPC A61K 35/76 (2013.01) [A01N 63/40 (2020.01); A61P 31/04 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12Q 1/18 (2013.01); A61K 38/00 (2013.01); C12N 2795/10122 (2013.01); C12N 2795/10131 (2013.01); C12N 2795/10132 (2013.01); C12N 2795/10171 (2013.01); C12N 2795/10222 (2013.01); C12N 2795/10231 (2013.01); C12N 2795/10232 (2013.01); C12N 2795/10271 (2013.01)]

11 Claims

1. An antibacterial composition comprising at least one bacteriophage having lytic activity against at least one Staphylococcus aureus (S. aureus) strain and a pharmaceutically acceptable excipient or carrier,

said at least one bacteriophage being selected from the bacteriophages having a genome comprising the nucleotide sequence of any one of SEQ ID NOs: 1 to 4 or a sequence having at least 95% identity thereto, and

said pharmaceutically acceptable excipient or carrier comprising a preservative in an amount effective to preserve the activity of the bacteriophage.